Dual Bronchodilator in the Era of Triple Therapy
暂无分享,去创建一个
N. Tzanakis | S. Loukides | N. Rovina | P. Steiropoulos | A. Papaioannou | P. Bakakos | E. Kosmas | G. Hillas | Evangellia Fouka | Georgios Patentalakis | M. Kouvela | E. Fouka | Epameinondas N Kosmas
[1] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[2] I. Pavord,et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline , 2020, European Respiratory Journal.
[3] C. Jenkins,et al. Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis , 2020, Respiratory Research.
[4] A. Agustí,et al. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection and Pneumonia Risk in Chronic Obstructive Pulmonary Disease: A Network Analysis. , 2020, American journal of respiratory and critical care medicine.
[5] P. Jones,et al. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis , 2020, Respiratory Research.
[6] S. Suissa,et al. Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD. , 2019, Chest.
[7] S. Suissa,et al. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD , 2019 .
[8] Meilan K. Han,et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.
[9] M. Tamm,et al. Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. , 2019, Chest.
[10] C. Vogelmeier,et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations , 2019, Respiratory Research.
[11] D. Kimuli,et al. A four-year trend in pulmonary bacteriologically confirmed tuberculosis case detection in Kampala-Uganda , 2019, BMC Pulmonary Medicine.
[12] Meilan K. Han,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.
[13] C. Bloom,et al. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016 , 2019, International journal of chronic obstructive pulmonary disease.
[14] B. Celli. Pharmacological Therapy of COPD: Reasons for Optimism. , 2018, Chest.
[15] Yong Jiang,et al. Role of TLR4-p38 MAPK-Hsp27 signal pathway in LPS-induced pulmonary epithelial hyperpermeability , 2018, BMC Pulmonary Medicine.
[16] M. Cazzola,et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis , 2018, European Respiratory Journal.
[17] P. Dorinsky,et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. , 2018, The Lancet. Respiratory medicine.
[18] P. Dorinsky,et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study , 2018, European Respiratory Journal.
[19] J. Wedzicha,et al. Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial , 2018, American journal of respiratory and critical care medicine.
[20] J. Wedzicha,et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.
[21] Meilan K. Han,et al. Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.
[22] N. Roche,et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.
[23] S. Rennard,et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.
[24] A. Ismaila,et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study , 2018, Respiratory Research.
[25] R. Barr,et al. Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort , 2018 .
[26] J. Wedzicha,et al. Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. , 2017, American journal of respiratory and critical care medicine.
[27] H. Magnussen,et al. Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.
[28] C. Janson,et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD , 2017, International journal of chronic obstructive pulmonary disease.
[29] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. , 2017, Respiratory medicine.
[30] D. Lomas,et al. FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease , 2017, American journal of respiratory and critical care medicine.
[31] J. Wedzicha,et al. How Do Dual Long‐Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? , 2017, American journal of respiratory and critical care medicine.
[32] J. Vestbo. Triple-Therapie mit einem Inhalator , 2017, Pneumologie.
[33] R. Suruki,et al. Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink , 2017, COPD.
[34] E. Wouters,et al. Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. , 2017, American journal of respiratory and critical care medicine.
[35] Dave Singh,et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.
[36] E. Kerwin,et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. , 2017, Respiratory medicine.
[37] J. Wedzicha,et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial , 2017, American journal of respiratory and critical care medicine.
[38] P. Calverley. A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.
[39] A. Morice,et al. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study , 2017, Lung.
[40] M. R. Siddiqui,et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .
[41] F. Martinez,et al. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co‐Suspension Delivery Technology in Patients With COPD , 2017, Chest.
[42] Dave Singh,et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.
[43] R. Tal-Singer,et al. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD , 2016, BMJ Open Respiratory Research.
[44] I. Pavord,et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.
[45] G. Ferguson,et al. Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study. , 2016, Chronic obstructive pulmonary diseases.
[46] C. Vogelmeier,et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study , 2016, European Respiratory Journal.
[47] P. Jones,et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD , 2016, International journal of chronic obstructive pulmonary disease.
[48] R. DiSantostefano,et al. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis , 2016, BMJ Open.
[49] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[50] H. Magnussen,et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. , 2016, The Lancet. Respiratory medicine.
[51] B. Nordestgaard,et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.
[52] E. Derom,et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study) , 2016, International journal of chronic obstructive pulmonary disease.
[53] E. Kerwin,et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[54] Dave Singh,et al. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial , 2015, BMC Pulmonary Medicine.
[55] J. Wedzicha,et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[56] A. Church,et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. , 2015, Respiratory medicine.
[57] Nuofu Zhang,et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD , 2015, International journal of chronic obstructive pulmonary disease.
[58] I. Pavord,et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.
[59] M. Cazzola,et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease , 2015, Expert opinion on drug safety.
[60] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.
[61] H. Watz,et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.
[62] N. Richard,et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. , 2014, Respiratory medicine.
[63] E. Bateman,et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study , 2014, BMC Pulmonary Medicine.
[64] Dave Singh,et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.
[65] M. Decramer,et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.
[66] V. Plaza,et al. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. , 2014, Chest.
[67] E. Kerwin,et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.
[68] B. Celli,et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. , 2014, Chest.
[69] Kayleigh Kew,et al. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[70] S. Suissa,et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.
[71] A. Church,et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.
[72] E. Bateman,et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.
[73] J. Wedzicha,et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.
[74] E. Bateman,et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.
[75] C. Brightling,et al. Eosinophils as diagnostic tools in chronic lung disease , 2013, Expert review of respiratory medicine.
[76] Christopher E Brightling,et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.
[77] A. Corrado,et al. How far is real life from COPD therapy guidelines? An Italian observational study. , 2012, Respiratory medicine.
[78] P. Jones,et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.
[79] Yoon K Loke,et al. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.
[80] David J Murphy,et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.
[81] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[82] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[83] A. Gonzalez,et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.
[84] I. Pavord,et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.
[85] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[86] B. Celli,et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.
[87] G. Donaldson,et al. COPD exacerbations · 1: Epidemiology , 2006, Thorax.
[88] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[89] B. Make,et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.
[90] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[91] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[92] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[93] P. Jones,et al. Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.
[94] L. Fabbri,et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[95] P. Barnes,et al. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. , 1997, American journal of respiratory and critical care medicine.
[96] R. Pistelli,et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. , 1995, The American journal of medicine.
[97] B. Balbi,et al. Lower respiratory tract inflammation in chronic bronchitis. Evaluation by bronchoalveolar lavage and changes associated with treatment with Immucytal, a biological response modifier. , 1994, Chest.
[98] J. Schouten,et al. Relationship of skin test reactivity and eosinophilia to level of pulmonary function in a community-based population study. , 1992, The American review of respiratory disease.
[99] P. Winkel,et al. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. , 1981, American journal of clinical pathology.